FRANKFURT Feb 22 Bayer, the German
drugmaker that is buying U.S. seed maker Monsanto, said
it expected a mid-single digit percentage increase in adjusted
core earnings for 2017, helped by fast growing revenues from
stroke prevention pill Xarelto.
In the fourth-quarter, profit before interest, taxes,
depreciation and amortisation (EBITDA), adjusted for one-off
items, rose 13.7 percent to 2.18 billion euros ($2.30 billion),
above the average estimate of 2.09 billion euros in a Reuters
poll of analysts.
($1 = 0.9493 euros)
(Reporting by Ludwig Burger; Editing by Victoria Bryan)